The Eli Lilly-backed firm has closed its oversubscribed fourth fund, LAV Biosciences Fund IV, reportedly raising the capital in only two months.
Lilly Asia Ventures, the Asia-focused biomedical venture capital firm sponsored by US-based pharmaceutical firm Eli Lilly, has closed its fourth fund at $450m, AltAssets reported yesterday.
LAV Biosciences Fund IV was heavily oversubscribed and took only two months to reach its hard cap, according to Alt Assets, though a regulatory filing indicates it was launched in February this year. It has not disclosed any limited partners apart from Eli Lilly.
Founded in 2008, Lilly Asia Ventures was formed by Eli Lilly…
